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Abstract: Seventeen new derivatives of the natural diterpene leubethanol, including some 
potential pro-drugs, with changes in the functionality of the aliphatic chain or modifications 
of aromatic ring and the phenolic group, were synthesized and tested in vitro by the MABA 
technique for their activity against the H37Rv strain of Mycobacterium tuberculosis. Some 
compounds showed antimycobacterial selectivity indices higher than leubethanol.  
Keywords: serrulatane derivatives; leubethanol; semi-synthesis; in vitro antimycobacterial 
activity; cytotoxicity assay 
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1. Introduction 
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) remains a worldwide health 
problem. According to the latest report from the World Health Organization (WHO), the number of 
people suffering from TB in 2013 was 9.0 million and approximately 1.5 million people died from the 
disease [1]. Moreover, Mtb is highly infectious; it is reported that about one third of the world’s 
population is latently infected, and that 10% of this population will develop active disease. A further 
significant problem is the association with HIV infection, from 1.5 million deaths caused by TB in 2013, 
0.36 million deaths were in HIV positive people. Therefore, TB-HIV co-infection is a major public 
health problem [1].  
The current first line drugs for TB treatment (isoniazid (INH), rifampicin (RIF), pyrazinamide and 
ethambutol) were discovered decades ago and are increasingly becoming less useful due to emerging 
multidrug-resistant (MDR), extended (XDR) or extremely (XXDR) resistant strains [2]. There were an 
estimate of 480,000 new cases of multidrug-resistant tuberculosis (MDR-TB) and 170,000 MDR-TB-related 
deaths. Treatment of MDR-TB disease requires high resources and at least the administration of RIF and 
INH in combination with second-line drugs. Second line drugs are more expensive, more toxic, and less 
effective than drugs used in standard therapy [3]. These facts have motivated the search for new drugs 
and treatment strategies. New drug candidates should shorten conventional chemotherapy and be 
effective against MDR-TB. 
Natural products have played an important role in the discovery of new drugs, as is the chemotherapy 
of tuberculosis [4,5], with the discovery of streptomycin, capreomycin, cycloserine, or development of 
rifamycin derivatives. Now, there is a re-emerging interest in natural products as novel template for the 
development of new drugs and particularly suitable as antibacterial leads [6–8]. Compounds bearing a 
serrulatane skeleton have been reported as good antimycobacterial agents [9–11].  
Waksman et al. isolated leubethanol (Leub), a natural serrulatane diterpenoid, from Leucophyllum 
frutescens methanolic extracts [10] and introduced different modifications on the skeleton to improve 
antimycobacterial activity [12]. Taking into account previous results of the research group on 
leubethanol structure modification related to antimycobacterial activity [12] and the information of 
similar structures reported in the literature [9,11], we intended to explore in the present study new 
possibilities to obtain better antimycobacterial compounds by introducing a glycosylated fragment on 
Leub phenolic hydroxyl, substitutions on the aromatic ring A, and new side-chain functionalizations 
(Figure 1). 
  
Figure 1. Leubethanol modifications on ring A and the alkyl side chain. 
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2. Results and Discussion 
2.1. Chemistry  
Leubethanol 8-O-β-D-glucopyranosyl derivative 1 was obtained with Schmidt trichloroacetimidate as 
glucosyl donor. Thus, Leub was treated with 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl 
trichloroacetimidate [13] and BF3·OEt as Lewis acid catalyst in dichloromethane [14] to give the  
8-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)leubethanol as the only adduct in 80% yield. When 
acetonitrile was used as reaction solvent instead of dichloromethane the reaction did not  
proceed [15]. In previous attempts to obtain the tetra-O-acetyl-glucopyranosyl Leub derivative by using 
2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide with potassium carbonate in chloroform [16], silver 
carbonate in pyridine [17], or transfer-phase catalysis with tetrabutylammonium bromide [18] no 
glycosidation product was obtained. 
Inversion of the anomeric carbon configuration of the 8-O-β-D-glucopyranosyl Leub derivative was 
established by a study of the H-1' coupling constant, with a value of 3.7 Hz in the glucopyranosyl 
trichloroacetimidate and of 7.9 Hz in the Leub aduct. Afterwards, the obtained Leub derivative was 
treated with sodium ethoxide in ethanol to provide compound 1 in 52% yield. Unequivocal structural 
assignment was achieved by 2D-NMR experiments (1H,1H-COSY, HMQC, HMBC). 
We introduced electron withdrawing groups (NO2, Br) on ring A. Leub treatment with 65% HNO3 
gave a mixture of 7-nitro and 5-nitro derivatives, (compounds 2 and 3, respectively) in 1.5:1.0 ratio. The 
unambiguous structural assignment of the nitrated derivatives was established by NOE experiments. 
Irradiation of the proton at 6.50 ppm on compound 2 showed a NOE effect on two of the methyls, the 
aromatic methyl at 2.21 ppm and the methyl doublet on the aliphatic chain at 0.83 ppm. On the other 
hand, irradiation of the proton at 6.63 ppm on compound 3 showed a NOE effect on the hydroxylic 
proton at 11.27 ppm and on the aromatic methyl at 2.57 ppm. The aliphatic double bond of Leub was 
hydrogenated with H2 in the presence of Pd-C catalyst, and the resulting 14,15-dihydroleubethanol 
treated with N-bromosuccinimide (NBS) to provide 7-bromoleubethanol (4) in 67% yield (Scheme 1). As 
just mentioned in the nitro derivatives, the bromine atom introduction at Leub position 7 was 
unequivocally established by NOE experiments. 
 
Scheme 1. Modifications of leubethanol on the phenolic hydroxyl and aromatic ring A.  
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dioxide. Treatment of compound 5 under Sharpless asymmetric epoxidation conditions (with  
L-(+)diethytartrate) gave the corresponding α-oxirane derivative 7 in 65% yield and ~91% ee. The allylic 
alcohol 5 was condensed with pyrazinecarboxylic acid in the presence of N,N-dicyclohexyl-carbodiimide 
(DCC) as coupling reagent to give the pyrazine ester derivative 8 in 53% yield. Compound 8 showed 
1H-NMR signals at 9.29 ppm (1H, d, J = 1.6 Hz), 8.75 ppm (1H, d, J = 2.4 Hz) and 8.73 (1H, dd, J = 2.4; 
1.6 Hz) of the pyrazine ring. Attempts to obtain other esters by treatment with 2-amino-isonicotinic acid 
or with 6-aminopyridine-3-carboxylic acid reaction did not progress, even by changing the coupling 
reagent (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, EDCI), the reaction solvent, or by increasing 
reaction time or the temperature.  
 
Scheme 2. Synthesis of leubethanol derivatives modified at the side chain. 
Furthermore, the α,β-unsaturated aldehyde 6 was used to obtain compounds 9–13. Treatment of 
compound 6 with hydroxylamine hydrochloride in dichloromethane/pyridine provided the hydroxyimine 
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84.5 ppm in the 13C-NMR), 2.73 ppm (1H, dd, J = 16.7, 14.5 Hz) and 2.35 ppm (1H, m) of the methylene 
(H-24) and at 7.39 (1H, d, J = 7.1 Hz, H-21) and 5.52 ppm (1H, d, J = 7.1 Hz, H-22) of the olefinic 
protons. Treatment of 6 with methylhydrazine in 2-propanol under refluxing conditions gave the 
pyrazole 11 with 55% yield [20]. Compound 11 showed in its 1H-NMR a one olefinic proton singlet at 
7.00 ppm (H-16) and a methyl at 3.75 ppm of the CH3-N. Two moles of 6 were treated with one mole 
of ethylenediamine in anhydrous toluene and a large excess of anhydrous sodium sulfate at room 
temperature to give a diimine 12a, which was reacted with sodium borohydride in ethanol to provide the 
ethylenediamine 12b, in a total yield of 86%. Finally, compound 6 was treated with sodium chlorite [21] 
to oxidize the aldehyde to an acid. The additional oxidation on the aromatic ring was observed. 
Compound 13 showed a quinone fragment with chemical shifts at 188.4 and 187.1 ppm of carbons C-5 
and C-8, respectively, in addition to a new carbonyl at 173.00 ppm of the acid group. Only one aromatic 
proton was appreciated in 1H-NMR at 6.52 ppm. To compare the influence of the quinone fragment on 
the antimycobacterial activity, we decided to obtain the quinone of Leub, compound 14. 
Promising antimycobacterial activity against Mtb H37Rv strain has been reported in the literature [9] 
for pseudopteroxazole and its analogue seco-pseudopteroxazole (MIC values of 97% and 66% 
mycocacterial growth inhibition at 12.5 μg/mL). Then, we decided to obtain the tricyclic diterpene 
analogue of Leub (Scheme 3). 
 
Scheme 3. Synthesis of the tricyclic derivative 18 from leubethanol.  
The phenol group was protected as an acetate by reaction of Leub with acetate anhydride in the 
presence of pyridine. Compound 15 showed a methyl group at 2.12 ppm in 1H-NMR and two acetyl 
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methanesulfonic acid in CH2Cl2 at −40 °C. Although the cyclization proceeded quantitatively, the 
product was a mixture of diastereomers 17a and 17b in a ratio of about 2:1. Compound 17a could be 
separated by silica gel chromatography, while compound 17b was obtained as a mixture of 17a and 17b. 
In the case of 17a, the vinyl proton attached to C(14) appeared at δ 4.99 as a broad doublet, J = 9.2 Hz 
while in 17b it was observed at δ 5.14 (doublet, J = 9.2 Hz). Compound 17a saponification with 
KOH/MeOH finally gave the phenol derivative 18. The overall yield from Leub to 18 was 41%. 
2.2. Antimycobacterial Activity  
The anti-MTB activity was assessed in vitro against the H37Rv strain (ATTC 27294) [22] susceptible 
to all SIREP anti-TB drugs, according to a modified Microplate Alamar Blue Assay (MABA) [23]. 
Ethambutol (EMB) was used as the reference drug and the assays were performed by triplicate 
independent experiments. Cytotoxicity on Vero cells [24] was also measured for those compounds with 
an appreciable in vitro anti-MTB effect. 
The in vitro antimycobacterial results of the Leub and seventten derivatives are shown in Table 1. 
The introduction of a glycoside fragment on the phenolic group induces the loss of the activity. We knew 
that the introduction of acyl or alkyl fragments at this position were not convenient for the activity, but 
we expected that the introduction of other hydroxyl groups (as is a glycoside) would not modify the 
activity results, so this indicates that phenol acidic properties are crucial for good activity. Substitutions 
at position 5 or 7 on Leub were also relevant for the antimycobacterial activity. We had previously found 
that the introduction of aromatic substituents on position 5 maintained Leub activity [12]. Taken into 
account the antimycobacterial activity results found for the pseudopterosins [9], compounds with an 
oxazole between positions 7 and 8 of the serrulatane skeleton, we expected to see good activity results 
for compounds substituted at position 7, like compounds 2 and 4, but they did not show activity. The 
antimycobacterial activity of compound 3 was a slightly lower than that of Leub, with small increase in 
the selectivity index. We planned to obtain the bromine derivative at position 5 to compare the 
antimycobacterial activity with compound 3, for this we had to previously protect the phenol group with 
a bulky group to force the introduction of the bromine at position 5, but in the process of removing the 
protecting group we got a mixture of compounds of difficult separation. As we indicated in the previous 
work functionalization of the C-16 methyl, compounds 5 and 6 showed similar potency and selectivity 
index to the natural compound leubethanol,  
Modifications of the aliphatic chain by introduction of an oxirane on the 14,15-double bond, 
(compound 7), or modifications on the alcohol or aldehyde functions, pyrazine ester 8, the hydroxyimine 
9, or the heterocyclic compounds 10 and 11 led to the loss of activity. Only Leub dimer 12a, tricyclic 
derivative 18 and especially the ethylenediamine 12b maintained the antimycobacterial activity. 
Regarding the Vero cells/Mtb selectivity, compounds 3, 5, 6 and 18 showed similar selectivity to 
leubethanol, and compound 12b twice as much as leubethanol.  
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Table 1. Antimycobacterial activity, cytotoxicity and selectivity index of leubethanol derivatives. 
 
 
Comp. 14,15- R1 R2 R3 R4 
MTB H37Rv
MIC (μM) 
Vero Cells 
CC50 (μM) 
Selectivity
Index (SI) 
Leub  H H H CH3 25.1 123 4.9 
1  Gluc H H H >200 nd -- 
2  H NO2 H CH3 >200 nd -- 
3  H H NO2 CH3 47.2 251 5.3 
4 -CH2-CH- H Br H CH3 >200 nd -- 
5  H H H CH2OH 25.8 132 5.1 
6  H H H CHO 25.8 116 4.5 
7 
 
H H H CH2OH >200 nd -- 
8  H H H CH2OCOC4H3N2 >200 nd -- 
9  H H H C=N-OH >200 nd -- 
10  H H H >200 nd -- 
11  >200 nd -- 
12a  100.1 nd -- 
12b  24.8 215 8.7 
13  >200 nd -- 
14  >200 nd -- 
18  55.1 173 3.1 
EMB  7.5 >500 >67 
MIC and CC50: rounded media values of three experiments; nd = no determined; --: not calculated; Selectivity 
index calculated by the equation: SI = CC50 (Vero)/MIC(H37Rv). EMB = Ethambutol. Gluc = β-D-glucopyranosyl. 
3. Experimental Section  
3.1. General Information  
All commercial chemicals and solvents used were reagent grade. Flash column chromatography was 
done using Merck Silica Gel 60 (0.04–0.063 mm). Reactions were monitored by TLC using Merck 
60F254 silica gel plates. Compounds were detected visually under UV irradiation (254 nm) and by 
spraying with sulfuric acid and phosphomolybdic acid reagents followed by heating at 100 °C. 1H-NMR 
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and 13C-NMR spectra were obtained with a Bruker AC 200 spectrometer (200 and 50.3 MHz, 
respectively). Chemical shifts were recorded in parts per million (ppm, δ) and were reported relative to 
the solvent peak or TMS. High resolution mass spectra (HRMS) were measured with a QSTAR XL 
quadrupole time-of-flight mass spectrometer, by direct injection on the sample dissolved in MeOH and 
Ionization voltage of 5500 V. Infrared (IR) spectra were measured on a Nicolet Impact 410 
spectrophotometer. The absorbances were measured with a Bio-Rad Benchmark model microplate 
reader. Middlebrook 7H9 broth medium was obtained from Difco® (Becton Dickinson and Co., Sparks, 
MD, USA) resazurin from Probiotek® (Hayward, CA, USA), and 0.45 μm pore size, 13 mm diameter 
PTFE from Millipore Millex® (Millipore Co., Bedford, MA, USA) Isoniazid, rifampicin, penicillin, 
streptomycin, and MTT were obtained from Sigma® (St. Louis, MO, USA) and fetal bovine serum from 
Hyclone® (Logan, UT, USA). 
3.2. Chemistry  
3.2.1. Preparation of 8-O-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl) leubethanol 
To a stirred solution of leubethanol (112 mg, 0.40 mmol) in dry CH2Cl2 (5 mL) at −20 °C, BF3·Et2O 
(75 μL, 0.60 mmol) with a syringe was added. Immediately, the suspension turned into a light-yellow 
solution. The mixture was stirred for 45 min and then, a solution of 2,3,4,6-tetra-O-acetyl-α-D-
glucopyranosyl trichloroacetimidate (292 mg, 0.59 mmol), recently obtained, in CH2Cl2 (2 mL) was 
added. The reaction was maintained for 4 h at room temperature. After that, the solution was diluted 
with CH2Cl2 and was washed with 10% NaHCO3, brine, water and dried over sodium sulphate. The 
organic layer was concentrated to give an oil, that was purified by column chromatography with  
n-hexane/ethyl acetate (95:5) as eluent to give 207 mg (80%) of 8-O-(2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosyl) leubethanol. IR: 2956, 2928, 2870, 1755, 1696, 1612, 1606, 1575, 1516, 1450, 1378, 
1226, 1108, 1043, 832, 750 cm−1; 1H-NMR (CDCl3): δ 0.95 (3H, d, J = 6.8 Hz), 1.11 (3H, d,  
J = 5.7 Hz), 1.1–1.3 (2H, m), 1.54 (3H, s), 1.65, (3H, s), 1.16–2.0 (7H, m), 2.03 (3H, s), 2.04 (3H, s), 
2.05 (3H, s), 2.09 (3H, s), 2.26 (3H, s), 2.53 (1H, m), 2.88 (1H, m), 3.89 (1H, m), 4.21 (2H, m), 5.00 
(1H, d, J = 6.8), 5.15 (1H, t, J = 8.8 Hz), 5.33 (3H, m), 6.71 (1H, s), 6.72 (1H, s); 13C-NMR (CDCl3): δ 
17.7, 18.8, 19.3, 20.7, 21.6, 22.7 (4C), 25.8, 26.2, 26.8, 27.5, 33.2, 42.4, 37.7, 62.4, 68.6, 71.2, 71.9, 
72.9, 99.3, 113.8, 124.9 (2C), 129.9, 131.1, 134.8, 140.9, 154.6; 169.3, 169.6, 170.4, 170.7; HRMS 
(ESI+) for C34H48O10Na [M+Na]+ calcd. 639.3145; found 639.3110. 
3.2.2. Preparation of 8-O-(β-D-Glucopyranosyl)leubethanol (1) 
2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl leubethanol (160 mg, 0.25 mmol) was dissolved in dry 
EtOH (5 mL) and a solution of sodium ethoxide (28 mg Na, 1.25 mmol) in EtOH was added. After 
stirring the mixture at room temperature for 2 h the reaction was completed. The solution was taken to 
dryness to obtain a residue that was purified by column chromatography with CH2Cl2/MeOH (8:2) as 
eluent to give 58 mg (52%) of compound 1. IR: 3412, 2923, 2862, 1652, 1612, 1575, 1458, 1376, 1268, 
1075, 841 cm−1; 1H-NMR (400 MHz, CDCl3): δ 0.95 (3H, d, J = 6.7 Hz), 0.96–1.30 (4H, m), 1.30 (3H, 
d, J = 6.8 Hz), 1.51 (3H, s), 1.60–2.0 (8H,m), 1.62 (3H, s), 2.24 (3H, s), 2.57 (1H, m), 3.28 (1H, m), 
3.32 (1H, m), 3.41 (1H, m), 3.49 (1H, m), 3.70 (1H, dd, J = 12.1, 5.8), 3.89 (1H, dd, J = 12.1, 2.0), 4.87 
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(1H, d, J = 7.3 Hz), 4.93 (1H, t, J = 6.8 Hz), 6.63 (1H, s), 6.79 (1H, s); 13C-NMR (50.3 MHz, CDCl3): δ 
17.7, 19.1, 20.3, 21.6, 22.2, 25.9, 27.4, 27.5, 28.6, 34.6, 39.5, 43.7, 62.7, 71.6, 78.1, 78.4, 75.2, 102.2, 
113.7, 124.6, 125.9, 132.5, 132.0, 136.0, 141.2, 156.6; HRMS (ESI+) for C26H41O6 [M+H]+ calcd. 
449.2903; found 449.2937. 
3.2.3. Preparation of 7-Nitroleubethanol (2) and 5-Nitroleubethanol (3) 
To a solution of leubethanol (56 mg, 0.19 mmol) in n-hexane (2 mL) 65% HNO3 (16 μL, 0.23 mmol) 
was added and the mixture stirred for 8 h. Then, ethyl acetate (30 mL) was added and the organic layer 
was washed with 5% NaHCO3, water and dried over Na2SO4. The solvent was removed under  
vacuum to provide a crude (60 mg), that was purified by silica flash chromatography using  
n-hexane/ethyl acetate (95:5) as eluent, to give 23 mg (37%) of 7-nitroleubethanol (2) and 16 mg (26%) 
of 5-nitroleubethanol (3). 
Compound 2. IR: 3450, 2959, 2927, 2870, 1606, 1575, 1516, 1453, 1352, 1239, 1181, 1128, 1052 cm−1; 
1H-NMR (CDCl3): δ 0.83 (3H, d, J = 6.8 Hz), 1.18 (3H, d, J = 6.8 Hz), 1.3–1.1 (2H, m), 1.52 (3H, s), 
1.65 (3H, s), 2.0–1.6 (7H, m), 2.21 (3H, s), 3.12 (2H, m), 4.93 (1H, t, J = 6.8 Hz), 5.37 (1H, br s), 6.50 
(1H, s); 13C-NMR (CDCl3): δ 17.6, 18.2, 18.5, 19.0, 21.5, 25.4, 25.7, 26.6, 26.7, 34.7, 37.7, 38.0, 114.7, 
124.5, 128.4, 129.0, 131.6, 134.0, 146.3, 154.1; HRMS (ESI+) for C20H29NO3Na [M+Na]+ calcd. 
354.2045; found 354.2042. 
Compound 3. IR: 2959, 2928, 2871, 1601, 1577, 1540, 1454, 1406, 1339, 1272, 1201, 1109, 1056 cm−1. 
1H-NMR (CDCl3) δ 0.99 (3H, d, J = 6.8 Hz), 1.19 (3H, d, J = 6.8 Hz), 1.3–1.1 (2H, m), 1.54 (3H, s), 
1.65 (3H, s), 2.0–1.6 (7H, m), 2.57 (3H, s), 3.24 (1H, m), 4.95 (1H, t, J = 6.8 Hz), 6.63 (1H, s), 11.27 
(1H, br s); 13C-NMR (CDCl3): δ 17.7, 18.8, 18.8, 22.9, 22.9, 25.8, 26.2, 26.9, 27.0, 33.4, 37.9, 42.9, 
124.5, 124.7, 131.5, 131.6, 132.2, 132.6, 140.9, 154.1; HRMS (ESI+) for C20H29NO3Na [M+Na]+ calcd. 
354.2045; found 354.2033. 
3.2.4. Preparation of 7-Bromo-14,15-dihydroleubethanol (4) 
A solution of leubethanol (306 mg, 1.1 mmol) in ethanol (10 mL) was treated with H2 under 10%  
Pd-C catalysis to provide 14,15-dihydroleubethanol in 95% yield [12]. Then, 14,15-dihydroleubethanol 
(54 mg, 0.18 mmol) was dissolved in carbon tetrachloride (3 mL) and NBS (35 mg, 0.20 mmol) was 
added. The mixture was refluxed for 4 h, followed to 1 h at 0 °C. The solid residue was filtered off and 
the solvent was evaporated under reduced pressure to give a crude oil that was purified by silica flash 
chromatography using n-hexane/ethyl acetate (98:2) as eluent giving 44 mg (67%) of compound 4. IR: 
3511, 2952, 2927, 2869, 1599, 1559, 1459, 1399, 1379, 1312, 1235, 1207, 1171, 1040, 980 cm−1.  
1H-NMR (CDCl3): δ 0.83 (6H, d, J = 6.8 Hz), 0.94 (3H, d, J = 6.8 Hz), 1.10–1.30 (2H, m), 1.19 (3H, d, 
J = 7.2 Hz), 1.50–2.0 (8H, m), 2.34 (3H, s), 2.54 (1H, m), 3.18 (1H, m), 5.65 (1H, br s), 6.66 (1H, s); 
13C-NMR (CDCl3): δ (ppm) 18.9, 19.4, 21.0, 22.6, 22.8, 23.0, 25.6, 27.2, 27.5, 28.0, 33.6, 38.5, 39.2, 
42.2, 110.4, 123.3, 128.2, 133.8, 139.9, 149.3; HRMS (ESI+) for C20H32BrO [M+H]+: calcd 367.1637; 
found 367.1646.  
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3.2.5. Preparation of 14,15-α-Epoxy-16-hydroxyleubethanol (7) 
L-(+)DET (60 μL, 0.34 mmol) was dissolved in CH2Cl2 (3.5 mL) under nitrogen and the solution 
cooled to −23 °C, then Ti(i-PrO)4 (300 μL, 6M) was added and the mixture stirred for 15 min. After that, 
a solution of compound 5 (25 mg, 0.08 mmol) in CH2Cl2 (1 mL) [12], was added and the mixture stirred 
for 5 min. Then, a solution of 3M of tert-butyl hydroperoxide (TBHP) in toluene (0.2 mL, 0.6 mmol) 
was added and the mixture stirred for 12 h. The reaction was quenched by the addition of a 10% aq. 
solution of tartaric acid (1 mL) and was stirred for 30 min at −23 °C, followed of 1 h at room temperature. 
The solution was filtered off through Celite, and the residue washed with diethyl ether. The organic layer 
was washed with water and reduced to a volume of 50 mL, treated with 1 M solution of NaOH (3 mL) 
at 0 °C for 45 min. The organic phase was washed with brine. The aqueous layer was extracted with 
Et2O and washed with brine. The combined organic layers were dried over sodium sulphate and 
concentrated to give an oil, which was purified by column chromatography with n-hexane/ethyl acetate 
(7:3) as eluent to give 13.6 mg (65%) of 14,15-α-epoxy-16-hydroxy-leubethanol (7) in ≈91% ee. IR: 
3408, 2951, 2927, 2869, 1616, 1580, 1457, 1421, 1377, 1332, 1285, 1254, 1035, 842 cm−1; 1H-NMR 
(CDCl3): δ 0.98 (3H, d, J = 6.8 Hz), 1.20 (3H, d, J = 6.8 Hz), 1.21 (3H, s), 2.24 (3H, s), 2.60 (1H, m), 
2.93 (1H, m), 3.07 (1H, m), 3.63 (2H, m), 4.77 (1H, br s), 6.43 (1H, s), 6.57 (1H, s); 13C-NMR (CDCl3): 
δ 14.2, 18.8, 21.1 (2C), 26.6, 26.6, 27.4, 30.0, 38.5, 39.2, 42.3, 60.4 (2C), 65.3, 114.4, 122.2, 126.3, 
135.3, 140.7, 153.1; HRMS (ESI) for C20H31O2 [M+H]+: calcd 303.2324; found 303.2369. 
3.2.6. Preparation of (E)-6R-((1S,4R)-5-Hydroxy-4,7-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-2-
methylhept-2-enyl pyrazine-2-carboxylate (8) 
A solution of pyrazinecarboxylic acid (13.6 mg, 0.11mmol), allylic alcohol 5 (31.5 mg. 0.1 mmol), 
and N,N-dicyclohexylcarbodiimide (22.7 mg, 0.11 mmol) in 5 mL of dichloromethane was stirred for 
24 h at room temperature. The mixture was filtered off and the filtrate washed with water, 5% HCl, and 
with water again, dried over sodium sulphate and the solvent removed under vacuum to give a crude oil 
that was purified by silica flash chromatography using n-hexane/ethyl acetate (9:1) as eluent to give  
10 mg (33%) of starting material and 22 mg (53%) of pyrazine ester derivative 8. IR: 3452, 2949, 2919, 
1702, 1616, 1580, 1453, 1332, 1247, 1001, 890 cm−1; 1H-NMR (CDCl3); δ 0.96 (3H, d, J = 6.8 Hz),  
1.1–1.6 (6H, m), 1.18 (3H, d, J = 7.2 Hz), 1.68 (3H, s), 1.9–2.1 (6H, m), 2.21 (3H, s), 2.56 (1H, m), 3.05 
(1H, m), 4.78 (2H, s), 5.47 (1H, t, J = 7.2 Hz), 6.43 (1H, s), 6.55 (1H, s), 8.73 (1H, dd, J = 1.6, 2,4 Hz); 
8.75 (1H, d, J = 2,4 Hz), 9.29 (1H, d, J = 1.6 Hz); 13C-NMR (CDCl3): δ 14.1, 18.7, 19.3, 21,1, 21.1, 
26.2, 26.6, 27.4, 32.8, 38.2, 42.3, 72.2, 113.3, 122.3, 126.3.128.9, 131.8, 135.1, 140.7, 143.6, 144.5, 
146.2, 147.5, 153.2, 163.8. HRMS (ESI+) for C25H32N2O3Na [M+Na]+: calcd 431.2311; found 431.2304. 
3.2.7. Preparation of 16-Hydroximinoleubethanol (9) 
The 16-oxoleubethanol 6 (43 mg, 0.14 mmol) dissolved in methanol (5 mL) was treated with 
hydroxylamine hydrochloride (97 mg, 1.4 mmol) and 5 drops of pyridine and the mixture was refluxed 
for 14 h. The solvent was removed under vacuum and the crude dissolved in dichloromethane, the 
organic layer was washed with water and dried over Na2SO4. Removal of the solvent gave 40 mg of a 
crude, that was purified by silica flash chromatography using n-hexane/ethyl acetate (9:1) as eluent, to 
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provide 20 mg (50%) of 9. IR: 3367, 2922, 2862, 1616, 1580, 1454, 1372, 1321, 1285, 1253, 1171, 1054, 
995 cm−1; 1H-NMR (CDCl3): δ 0.99 (3H, d, J = 6.8 Hz), 1.3–1.6 (4H, m), 1.20 (3H, d, J = 6.8 Hz), 1.77 
(3H, s), 1.8–2.2(6H, m), 2.24 (3H, s), 2.60 (1H, m), 3.06 (1H, m), 5.59 (1H, t, J = 7.6 Hz), 6.43 (1H, s), 6.56 
(1H, s), 7.66 (1H, s), 8.10 (1H, br s); 13C-NMR (CDCl3): δ 11.9, 18.6, 19.2, 21.0, 21.4, 26.5, 26.5, 27.5, 
32.5, 38.2, 42.2, 113.3, 122.3, 126.2, 130.2, 135.2, 139.9, 140.6, 153.0, 154.9; HRMS (ESI+) for 
C20H30NO2 [M+H]+ calcd. 316. 2277; found 316.2271. 
3.2.8. Preparation of 2-((E)-6R-((1S,4R)-5-Hydroxy-4,7-dimethyl-1,2,3,4-tetrahydronaphthalen-1-
yl)hept-2-en-2-yl)-2H-pyran-4(3H)-one (10) 
To a solution of trans-methoxytrimethylsilyloxy-1,3-butadiene (40 mg, 0.23 mmol) in dry diethyl 
ether (5 mL) under nitrogen atmosphere at −30 °C aldehyde 6 (75 mg, 0.23 mmol) dissolved in diethyl 
ether (2 mL) and boron trifluoride diethyl etherate (45 μL, 0.23 mmol) were added. The mixture was 
maintained for 4 hours under stirring and the reaction was quenched by the addition of Et3N (96 μL,  
0.69 mmol) and water (2 mL). The mixture was treated with diethyl ether, washed with brine and the 
organic layer dried with Na2SO4. The crude was dissolved in dichloromethane (5 mL) and 4 drops of 
trifluoroacetic acid was added. One hour later, the solvent was evaporated under reduced pressure to 
give a crude that was purified by silica flash chromatography using n-hexane/ethyl acetate (9:1) as eluent 
giving 20 mg (26%) of starting material and 38 mg (48%) of dihydropyranone derivative 10. IR: 3402, 
2953, 2923, 2869, 1661, 1588, 1502, 1454, 1413, 1278, 1226, 1174, 1050, 984 cm−1; 1H-NMR (CDCl3): 
δ 0.99 (3H, d, J = 6.8 Hz), 1.19 (3H, d, J = 6.9 Hz), 2.23 (3H, s), 2.35 (3H, s), 2.59 (1H, m), 2.73 (1H, 
dd, J = 16.7, 14.5 Hz), 3.08 (1H, m). 4.69 (1H, dd, J = 14.5, 2.4 Hz), 5.42 (2H, m), 6.44 (1H, s), 6.56 
(1H, s), 7.39 (1H, dt, J = 6.1, 1.0 Hz); 13C-NMR (CDCl3): δ 11.9, 18.7, 19.2, 21.1, 21.1, 26.0, 26.5, 27.5, 
32.7, 38.2, 40.6, 42.2, 84.5, 106.7, 113.3, 122.2, 126.3, 130.8, 131.2, 135.0, 140.6, 153.2, 163.6, 193.2; 
HRMS (ESI+) for C24H32O3Na [M+Na]+ calcd. 391.2249; found 391.2239. 
3.2.9. Preparation of (5S,8R)-5-((2R)-4-(1,4-Dimethyl-1H-pyrazol-3-yl)butan-2-yl)-3,8-dimethyl-
5,6,7,8-tetrahydronaphthalen-1-ol (11) 
To a stirring solution of 16-oxoleubethanol 6 (19 mg, 0.06 mmol) in 2-propanol (2 mL), 
methylhydrazine (26 μL, 0.5 mmol) was added and the mixture refluxed for 5 hours. The solvent was 
removed under reduced pressure to give a crude oil that was purified by silica flash chromatography 
using n-hexane/ethyl acetate (9:1) as eluent to give 11 mg (55%) of the pyrazole 11. IR: 3209, 2929, 
2864, 1613, 1578, 1451, 1419, 1371, 1321, 1285, 1260, 1172, 1059 cm−1. 1H-NMR (CDCl3): δ 1.02 (3H, 
d, J = 6.8 Hz), 1.10–1.30 (2H, m), 1.18 (3H, d, J = 7.2 Hz), 1.50–203 (8H, m), 1.85 (3H, s), 2.20 (3H, 
s), 2.59 (1H, m), 3.02 (1H, m), 3.75 (3H, s), 5.31 (1H, br s), 6.40 (1H, s), 6.50 (1H, br s), 7.00 (1H, br 
s); 13C-NMR (CDCl3): δ 8.2, 18.7, 19.6, 21.1, 21.2, 25.0, 26.7, 27.5, 33.0, 38.2, 38.3, 42.4, 113.2, 113.5, 
122.2, 126.3, 129.5, 135.0, 140.8, 151.5, 153.3; HRMS (ESI+) for C21H31N2O [M+H]+: calcd 327.2436; 
found 367.2439. 
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3.2.10. Preparation of (5S,5'S,8R,8'R)-5,5'-((2R,2'R,5E,5'E,7Z,7'Z)-7,7'-(Ethane-1,2-diylbis(azan-1-yl-
1-ylidene))bis(6-methylhept-5-ene-2-yl-7-ylidene))bis(3,8-dimethyl-5,6,7,8-tetrahydronaphthalen-1-
ol) (12a) 
To a solution of compound 6 (91 mg, 0.3 mmol) in dry toluene (1.5 mL), ethyendiamine (10 mL,  
0.15 mmol) and anhydrous Na2SO4 (900 mg) were added. The mixture was maintained at room 
temperature for 19 h. The solid was filtered, and the solvent was removed under reduced pressured to 
isolated 92 mg (95%) of the diimine derivative 12a. IR: 3447, 2925, 1654, 1624, 1458, 1119 cm−1.  
1H-NMR (CDCl3): δ 0.96 (3H, d, J = 7.6 Hz), 1.18 (3H, d, J = 6.8 Hz), 1.20–1.60 (4H, m), 1.76 (3H, s), 
1.8–2.10 (6H, m), 2.19 (3H, s), 2.56 (1H, m), 3.07 (1H, m), 3.70 (2H, s), 5.69 (1H, t, J = 6.8 Hz), 6.38 
(1H, s), 6.51 (1H, s), 7.69 (1H, s); 13C-NMR (CDCl3) δ 12.4, 19.6, 20.0 (2C), 22.0, 27.5, 27.7, 28.4, 
33.3, 39.2, 43.1, 62.1, 114.1, 122.7, 127.5, 135.9, 136.3, 141.5, 144.1, 154.5, 168.7. HRMS (ESI+) for 
C42H61N2O2 [M+H]+ calcd. 625.4732; found 625.4728. 
3.2.11. Preparation of (5S,5'S,8R,8'R)-5,5'-((2R,2'R,5E,5'E)-7,7'-(Ethane-1,2-diylbis(azanediyl))-bis(6-
methylhept-5-ene-7,2-diyl))bis(3,8-dimethyl-5,6,7,8-tetrahydronaphthalen-1-ol) (12b) 
Diimine 12a (83 mg, 0.13 mmol) was dissolved in ethanol (2 mL), and a solution of NaBH4 (10 mg,  
0.26 mmol) in anhydrous ethanol (1 mL) was added. The mixture was maintained for 3 h at 40 °C, 
cooled, diluted with water (5 mL), treated with a 5% NaOH, and extracted with dichloromethane. The 
organic layer was washed with brine, dried over K2CO3, and the solvent was removed under reduced 
pressure to isolated 79 mg (90%) of ethylendiamine derivative 12b. IR: 3450, 2925, 1654, 1617, 1578, 
1458, 840 cm−1.1H-NMR (CDCl3): δ 0.89 (3H, d, J = 6.8 Hz), 1.00–1.25 (4H, m), 1.11 (3H, d, J = 6.0 Hz), 
1.50–2.0 (8H, m), 1.75 (3H, s), 2.15 (3H, s), 2.50 (1H, m), 2.52 (1H, m), 3.01 (2H, m), 5.09 (1H, br. s), 
6.33 (1H, s), 6.48 (1H, s); 13C-NMR (CDCl3): δ 14.7, 18.8, 19.4, 21.2 (2C), 26.1, 26.6, 26.5, 33.2, 38.2, 
42.4, 47.7, 57.3, 113.3, 121.7, 126.8, 127.5, 132.4, 134.8, 140.7, 153.9; HRMS (ESI+) for C42H65N2O2 
[M+H]+ calcd. 629.5042; found 629.5038. 
3.2.12. Preparation of (R,E)-6-((1S,4R)-4,7-Dimethyl-5,8-dioxo-1,2,3,4,5,8-hexahydronaphthalen-1-
yl)-2-methylhept-2-enoic acid (13) 
The aldehyde 6 (60 mg, 0.17 mmol) was dissolved in tert-butyl alcohol (4 mL) and 2-methyl-2-butene 
(1 mL). Then, a solution of sodium chlorite (141 mg, 1.56 mmol) and sodium hydrogen phosphate  
(126 mg, 1.05 mmol) in water (2 mL) was added dropwise over a 10 minute period. The reaction mixture 
was stirred at room temperature overnight. The solvent was removed under reduced pressured, and the 
residue dissolved in water (10 mL) and extracted with hexane (2 × 8 mL). The combined organic layers 
were dried with Na2SO4, filtered and evaporated under reduced pressure to give 40 mg (72%) of the 
quinone 13. IR: 3520, 2930, 2870, 1710, 1690, 1660, 1606, 1516, 1453, 1281, 1128, 890 cm−1; 1H-NMR 
(CDCl3): δ 0.85 (3H, d, J = 6.8 Hz), 1.06 (3H, d, J = 6.8 Hz), 1.10–1.30 (2H, m), 1.79 (3H, s), 1.60–2.20 
(7H, m), 2.00 (3H, s), 2.78 (1H, m), 2.93 (1H, m), 6.52 (1H, s), 6.80 (1H, t, J = 6.8 Hz), 8.20 (1H, br s); 
13C-NMR (CDCl3): δ 11.9, 15.8, 18.5, 19.3, 21.0, 25.2, 26.6, 26.8, 33.4, 35.8, 36.7, 127.1, 133.4, 144.9, 
145.0, 145.4, 147.4, 173.2, 187.1, 188.4; HRMS (ESI+) for C20H26O4Na [M+Na]+ calcd. 353.1729; 
found 353.1714. 
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3.2.13. Preparation of (5R,8S)-2,5-Dimethyl-8-((E,R)-6-methylhept-5-en-2-yl)-5,6,7,8-
tetrahydronaphthalene-1,4-dione (14) 
Leubethanol (74 mg, 0.26 mmol) was dissolved in in tert-butyl alcohol (9 mL) and  
2-methyl-2-butene (2 mL). Then, a solution of sodium chlorite (216 mg, 3.4 mmol) and sodium hydrogen 
phosphate (210 mg, 1.8 mmol) in water (2 mL) was added dropwise over a 10 minute period. The 
reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced 
pressured, the residue dissolved in 10 mL of water and extracted with hexane (2 × 10 mL). The combined 
organic layers were dried with Na2SO4, filtered and evaporated under reduced pressure to give 30 mg of 
starting material and 35 mg (48%) of the quinone 14. IR: 2957, 2926, 1718, 1676, 1601, 1540, 1410, 
1272, 1201, 1109, 890 cm−1; 1H-NMR (CDCl3): δ 0.78 (3H, d, J = 6.8 Hz), 1.01 (3H, d, J = 6.8 Hz), 
1.10–1.40 (2H, m), 1.49 (3H, s),1.58 (3H, s), 1.60–2.20 (7H, m), 1.95 (3H, s), 2.70 (1H, m), 2.87 (1H, 
m), 4.93 (1H, t, J = 7.2 Hz); 6.44 (1H, s); 13C-NMR (CDCl3): δ 15.7, 17.6, 18.7, 19.0, 21.1, 25.6, 25.7, 
26.3, 26.5, 34.8, 36.6, 37.6, 124.1, 131.5, 133.4, 143.2, 145.5, 147.0, 187.3, 188.4; HRMS (ESI+) for 
C20H29O2 [M+H]+ calcd. 301.2168; found 301.2164. 
3.2.14. Preparation of 8-Acetoxyleubethanol (15) 
Distilled Ac2O (0.5 mL) was added to a solution of leubethanol (97 mg, 0.33 mmol) in pyridine  
(2 mL). After 12 hours the reaction was quenched with ice, one hour later the mixture was extracted with 
EtOAc and the organic layer was washing with 10% HCl, 5% NaHCO3, brine and finally dried over 
Na2SO4.The solvent was evaporated under reduced pressure to give a crude oil that was purified by 
chromatography on silica gel n-hexane/EtOAc (95:5) to give 104 mg of acetylated Leub, compound 15 
(95%). IR: 2954, 2926, 2870, 1765, 1619, 1571, 1451, 1370, 1207, 1048 cm−1. 1H-NMR (CDCl3): δ 0.99 
(3H, d, J = 7.1 Hz, 3H), 1.15 (3H, d, J = 6.8 Hz), 1.59 (3H, s), 1.68 (3H, s), 2.31 (6H, s), 2.61 (1H, m), 
2.95 (1H, m), 5.01 (1H, t, J = 7.1 Hz), 6.70 (1H, s), 6.88 (1H, s); 13C-NMR (CDCl3): δ 17.7, 18.8, 19.3, 
21.2 (2C), 21.8, 25.8, 26.3, 27.2, 27.4, 33.2, 38.0, 42.3, 120.3, 124.9, 127.6, 131.2, 131.6, 135.1, 141.2, 
148.7, 169.7; HRMS (ESI+) for C22H33O2 [M+H]+: calcd. 329.2481; found 329.2502. 
3.2.15. Preparation of (5S,8R)-5-((E,R)-6-Hydroxy-6-methylhept-4-en-2-yl)-3,8-dimethyl-5,6,7,8-
tetrahydronaphthalen-1-yl acetate (16) 
To a magnetic stirred, ice-cooled solution of diphenyldiselenide (590 mg, 1.89 mmol) in dry 
dichloromethane (7 mL) was slowly added chilled 33% of hydrogen peroxide (0.21 mL, 64.2 mg,  
1.89 mmol). After stirring vigorously for 30 min (white crystals deposit within 10 min), powered 
anhydrous magnesium sulfate (300 mg) was added and the mixture was stirred for an additional 30 min 
in the ice-bath. The ice bath was removed, compound 15 (408 mg, 0.86 mmol) was added and the mixture 
stirred vigorously for 6 h at 25 °C. Chilled 3M tert-butyl hydroperoxide (1.4 mL, 4.3 mmol) was added 
to the reaction mixture which had been immersed in an ice bath; then, after removing the ice bath, the 
mixture was stirred for 20 h at 25 °C to give a pale orange solution with a lot of white precipitated. The 
white precipitate (PhSeO2H and hydrated MgSO4), was filter off and washed with ethyl acetate. The 
filtrate was concentrated to give an oil. The oil was dissolved in ethyl acetate (100 mL) and washed with 
5% Na2CO3 water, 10% FeSO4, water, (sat)NaHCO3, water and brine, successively and then, it was dried 
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over Na2SO4. The solvent was evaporated under reduced pressure to give a crude oil that was purified 
by chromatography on silica gel n-hexane/ethyl acetate (98:2) to give 152 mg of starting material and 
245 mg (56%) of allyl alcohol 16. IR: 3454, 2950, 2922, 2872, 1763, 1618, 1571, 1453, 1370, 1207, 
1140, 971, 881 cm−1. 1H-NMR (CDCl3): δ 0.95 (3H, d, J = 6.8 Hz), 1.12 (3H, d, J = 6.8 Hz), 1.22 (3H, 
s), 1.23 (3H, s), 2.28 (3H, s), 2.29 (3H, s), 2.62 (1H, m), 2.91 (1H, m), 5.3–5.6 (2H, m), 6.67 (1H, s), 
6.87 (1H, s); 13C-NMR (CDCl3): δ 18.8, 19.3, 21.1, 21.1, 21.6, 27.2, 27.2, 29.7, 29.8, 36.3, 39.3, 41.6, 
70.6, 120.4, 126.3, 127.8, 131.6, 135.3, 139.0, 141.1, 148.7, 169.8; HRMS (ESI+) for C22H32O3Na 
[M+Na]+: calcd. 367.2249; found 367.2295. 
3.2.16. Preparation of (3R,7S,9R,9aS)-3,6,9-Trimethyl-7-(2-methylprop-1-enyl)-2,3,7,8,9,9a-
hexahydro-1H-phenalen-4-yl acetate (17a) and (3R,7R,9S,9aS)-3,6,9-Trimethyl-7-(2-methylprop-1-
enyl)-2,3,7,8,9,9a-hexahydro-1H-phenalen-4-yl acetate (17b) 
A solution of allylic alcohol 16 (70 mg, 0.20 mmol) was cooled to −78 °C and treated dropwise with 
methanesulfonic acid (65 μL, 1.0 mmol). The solution was warmed to −40 °C and stirred for 12 h, and 
then triethylamine (0.50 mL) was added. The mixture was warmed to 20 °C, filtered off through a small 
plug of silica gel with hexane, and concentrate in vacuo to afford 63 mg (97%) of a mixture of 
compounds 17a + 17b (2:1). 
Compound 17a. IR: 2925, 2863, 1762, 1598, 1452, 1370, 1209, 1036 cm−1. 1H-NMR (CDCl3): δ 0.86 
(3H, d, J = 7.1 Hz), 1.19 (3H, d, J = 6.9 Hz), 1.67 (3H, s), 1.72 (3H, s), 2.12 (3H, s), 2.29 (3H, s), 2.70 
(1H, m), 3.02 (1H, m), 3.65 (1H, m), 5.16 (1H, m), 6.68 (1H, s); 13C-NMR (CDCl3): δ 16.0, 17.6, 19.9, 
21.1, 22.7, 25.3, 27.1, 28.6, 30.8, 31.5, 34.7, 37.3, 39.9, 121.7, 128.8, 131.4, 132.6, 135.0, 135.5, 137.2, 
146.9, 169.7; HRMS (ESI+) for C22H30O2Na [M+Na]+: calcd. 349.2143; found 349.2154. 
Compound 17b. IR: 2925, 2863, 1762, 1598, 1452, 1370, 1209, 1036 cm−1. 1H-NMR (CDCl3) δ 0.72 
(3H, d, J = 7.1 Hz), 1.20 (3H, d, J = 6.9 Hz), 1.68 (3H, s), 1.72 (3H, s), 2.13 (3H, s), 2.29 (3H, s), 2.70 
(1H, m), 3.02 (1H, m), 3.63 (1H, m), 3.82 (1H, ddd, J = 8.7, 8.7, 8.7 Hz); 5.01 (1H, br d,  
J = 8.7 Hz,), 6.66 (1H, br s); 13C-NMR (CDCl3): δ 13.6, 17.4, 20.0, 21.1, 23.0, 25.4, 27.2, 28.7, 31.2, 
31.4, 33.6, 37.5, 40.3, 121.6, 129.0, 129.8, 131.3, 135.1, 135.2, 138.1, 149.6, 169.7. 
3.2.17. Preparation of (3R,7S,9R,9aS)-3,6,9-Trimethyl-7-(2-methylprop-1-enyl)-2,3,7,8,9,9a-
hexahydro-1H-phenalen-4-ol (18) 
Acetyl compound 17a (53 mg, 0.16 mmol) was dissolved in KOH/MeOH (5 mL, 2M) and stirred for 
12 h. After that time, the solvent was evaporated, the residue was dissolved in water and extracted with 
ethyl acetate. The organic layer was dried over Na2SO4, and the solvent was evaporated under reduced 
pressure to give a crude oil that was purified by chromatography on silica gel n-hexane/ ethyl acetate 
(98:2) to give 35 mg 63%) of alcohol compound 18. IR: 3516, 2958, 2921, 2866, 1589, 1450, 1412, 
1377, 1237, 1177, 1031, 908, 732 cm−1. 1H-NMR (CDCl3): δ 0.70 (3H, d, J = 7.0 Hz); 1.28 (3H, d,  
J = 6.8 Hz); 1.67 (3H, s); 1.71 (3H, s); 2.10 (3H, s); 2.68 (1H, m); 3.11 (1H, m); 3.61 (1H, q,  
J = 9.0 Hz); 4.98 (1H, dt, J = 9.3, 1.3 Hz); 6.42 (1H, s); 13C-NMR (CDCl3): δ 13.3, 17.4, 19.9, 22.8, 
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27.8, 28.5, 29.4, 31.4, 32.0, 33.2, 37.7, 40.8, 115.4, 125.7, 128.4, 129.6, 130.6, 135.1, 138.8, 151.4. 
HRMS (ESI+) for C20H29O [M+H]+: calcd. 385.2218; found 385.2255. 
3.3. In Vitro Antimycobacterial Evaluation  
The antimycobacterial activity was assessed against M. tuberculosis H37Rv ATTC 27294 susceptible 
to all five first-line anti-TB drugs (streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide) in 
a modified Microplate Assay Blue Alamar [22,23]. The compounds for M. tuberculosis bioassays were 
prepared at a concentration of 1 mg/mL in 2.5% DMSO in Middlebrook 7H9 (Becton Dickinson and 
Co., Sparks, MD, USA) broth. All solutions were sterilized by filtration using 13 mm diameter PTFE 
acro-discs (0.22 μm pore size, Millipore Co., Bedford, MA, USA). The concentrations for organic 
compounds used ranged from 100 μg/mL to 0.78 μg/mL, results are reported as minimal inhibition 
concentration (MIC). Ethambutol (EMB) was used as positive control. All biological assays were 
developed at least by triplicate. 
3.4. Cytotoxicity Assay  
Cytotoxicity was determined according to the MTT method [24] using African green monkey kidney 
epithelial cells (Vero cells) grown in RPMI-1640 medium supplemented with penicillin (100 units/mL), 
streptomycin (100 μg/mL), and fetal bovine serum (10%) at 37 °C under 5% CO2. In the confluence, 
4000 cells per well was applied to a 96-well microtitre plate. After incubation for 24 h (37 °C, 5% CO2), 
10 μL of a solution containing concentrations ranging from 500 to 0.5 μg/mL of the compound under 
evaluation was added and incubated for 48 h. 25 μL of MTT (4 mg/mL in PBS) was added to each well 
and incubated for another 3 h. The solution in each well was removed and DMSO (200 μL) was then 
added to each well. The absorbance was recorded on a microplate reader at a wavelength of 575 nm. The 
CC50 value was calculated by linear regression as the concentration of the compound inhibiting 50% 
cellular viability. 
4. Conclusions  
The results found in this study regarding the antimicrobial activity indicate that there are few 
possibilities of modification on the leubethanol molecule. The dimer of leubethanol, compound 12b 
showed a higher selectivity index than the natural compound. 
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